Regeneron Pharmaceuticals (REGN) Other Operating Expenses (2009 - 2026)

Regeneron Pharmaceuticals' Other Operating Expenses history runs 18 years deep, the most recent figure standing at $703.5 million for Q2 2026.

• In Q2 2026, Other Operating Expenses changed N/A year-over-year to $703.5 million; the TTM figure through Jun 2026 stood at $1.5 billion (up 6418.3% YoY), while the FY2025 annual figure was $10.0 million, up 118.73% from the prior year.
• Other Operating Expenses for Q2 2026 stood at $703.5 million, down from $771.3 million in the prior quarter.
• The five-year high for Other Operating Expenses was $771.3 million in Q1 2026, with the low at -$15.5 million in Q4 2024.
• The 5-year median for Other Operating Expenses is $600000.0 (2023), against an average of $101.6 million.
• The sharpest annual moves came in 2024 and 2025: Other Operating Expenses slumped 3200.0% in 2024, then soared 225.0% in 2025.
• Regeneron Pharmaceuticals' Other Operating Expenses stood at $6.6 million in 2022, then sank by 92.42% to $500000.0 in 2023, then plunged by 3200.0% to -$15.5 million in 2024, then surged by 164.52% to $10.0 million in 2025, then soared by 6935.0% to $703.5 million in 2026.
• Business Quant data shows REGN's Other Operating Expenses at $703.5 million in Q2 2026, $771.3 million in Q1 2026, and $10.0 million in Q3 2025.